IMMIX BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
IMMIX BIOPHARMA, INC. (IMMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 18.11 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 18.11K shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 17.76K shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 1.77K shares, a 324.70% increase year-over-year.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 39.52K shares, a 120.60% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 17.91K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 18.11K shares 10-Q · filed 2026-08-07 | 35.88K shares derived: sum of 3 quarters · filed 2026-08-07 | 37.65K shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 18.11K shares 10-Q · filed 2026-05-07 | 35.88K shares derived: sum of 2 quarters · filed 2026-05-07 | 37.65K shares derived: sum of 3 quarters · filed 2026-05-07 | |
| 2025-12-31 | 17.76K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 19.53K shares derived: sum of 2 quarters · filed 2026-03-27 | 39.52K shares 10-K/A · filed 2026-03-27 | |
| 2025-09-30 | 1.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 21.76K shares 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | 19.99K shares 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 417.00 shares derived: sum of 2 quarters · filed 2026-03-27 | 17.91K shares 10-K/A · filed 2026-03-27 | |
| 2024-09-30 | 417.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 17.91K shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 17.50K shares 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |